215522-96-6

Upstream product

• 247186-56-7 tert-butyl 3-formylbenzoate 
• 126062-63-3 1,1-dimethylethyl 3-bromomethylbenzoate 

Downstream Products

• 128473-00-7 3-(N,N'-Diisopropyl-carbamimidoyloxymethyl)-benzoic acid tert-butyl ester 
• 128472-67-3 (6R,7S)-3-Acetoxymethyl-7-methoxy-5,5,8-trioxo-5λ⁶-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 3-carboxy-benzyl ester 

Relevant academic research and scientific papers

AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR

The present invention provides a GPR receptor function regulator comprising the compound represented by the formula: [wherein ring A is an optionally substituted isocyclic or heterocyclic ring, P is a bond or spacer, ring D is an optionally substituted monocyclic aromatic ring which may be condensed with a 5-to 7-membered ring, V is a bond or the group represented by the formula -CR14=CR15 - or - N=CR16- (wherein R14, R15 and R16 each represents a hydrogen atom or optionally substituted hydrocarbon group), Q is a bond or spacer, and W is a carboxyl or a group biologically equivalent to a carboxyl] or its salt or a prodrug thereof

Protease inhibitors

The present invention provides compounds of formula (I) which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia or malignancy; and metabolic bone disease therewith.